Loading...

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

ePostersLive by SciGen Technologies S.A. All rights reserved.

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Posters by Code

Showing 1,267 results.

Thumbnail for Modulation of the Hepcidin Pathway Produces Homogeneous Erythropoietic Suppression but Heterogeneous Iron Repletion in Polycythemia Vera: Lessons from REVIVE and IMPRSSION.

MPN - 908

Modulation of the Hepcidin Pathway Produces Homogeneous Erythropoietic Suppression but Heterogeneous Iron Repletion in Polycythemia Vera: Lessons from REVIVE and IMPRSSION.

Ashiya Loomba

Poster Presenter: Ashiya Loomba

Thumbnail for Ribosomal Stoichiometric Reprogramming and Integrated Stress Response Activation Define a Translational Stalling State in DLBCL Non-Responder CAR-T Infusion Products

ABCL - 910

Ribosomal Stoichiometric Reprogramming and Integrated Stress Response Activation Define a Translational Stalling State in DLBCL Non-Responder CAR-T Infusion Products

Ali Turunc

Poster Presenter: Ali Turunc

$Thumbnail for Early Real-World Outcomes of Revumenib Versus Venetoclax-Based Salvage Therapy in Relapsed or Refractory Acute Leukemia$

AML - 911

Early Real-World Outcomes of Revumenib Versus Venetoclax-Based Salvage Therapy in Relapsed or Refractory Acute Leukemia

Vishw Patel

Poster Presenter: Vishw Patel

Thumbnail for Outcomes of Ruxolitinib in Adult Patients with Acute Lymphoblastic Leukemia After Allogeneic Hematopoietic Cell Transplantation: A Propensity Score-Matched Real-World Analysis

ALL - 912

Outcomes of Ruxolitinib in Adult Patients with Acute Lymphoblastic Leukemia After Allogeneic Hematopoietic Cell Transplantation: A Propensity Score-Matched Real-World Analysis

Ali Turunc

Poster Presenter: Ali Turunc

Thumbnail for Asciminib vs Dasatinib/Nilotinib as First-Line Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: A Propensity Score-Matched Analysis of Disease Progression and Safety Outcomes

CML - 913

Asciminib vs Dasatinib/Nilotinib as First-Line Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: A Propensity Score-Matched Analysis of Disease Progression and Safety Outcomes

Ali Turunc

Poster Presenter: Ali Turunc

Thumbnail for Metabolic Autonomy of Cytotoxic Programs Distinguishes Responder from Non-Responder CAR-T Effectors in DLBCL: A Single-Cell Co-Expression Network Analysis

ABCL - 914

Metabolic Autonomy of Cytotoxic Programs Distinguishes Responder from Non-Responder CAR-T Effectors in DLBCL: A Single-Cell Co-Expression Network Analysis

Ali Turunc

Poster Presenter: Ali Turunc

Thumbnail for Comparative Outcomes of CD38 Antibody-Containing Four-Drug Induction Strategies vs Standard Triplet Therapy in High-Risk Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis

MM - 915

Comparative Outcomes of CD38 Antibody-Containing Four-Drug Induction Strategies vs Standard Triplet Therapy in High-Risk Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis

Jasvindar Kumar

Poster Presenter: Jasvindar Kumar

Thumbnail for Real-World Outcomes of Pirtobrutinib Versus Venetoclax After Covalent BTK Inhibitor Exposure in CLL/SLL

CLL - 916

Real-World Outcomes of Pirtobrutinib Versus Venetoclax After Covalent BTK Inhibitor Exposure in CLL/SLL

Vishw Patel

Poster Presenter: Vishw Patel

Thumbnail for Clonal Hematopoiesis of Indeterminate Potential Mutations in Neuroendocrine Tumor Patients: Cluster Analysis and Application of Risk Scores

AML - 917

Clonal Hematopoiesis of Indeterminate Potential Mutations in Neuroendocrine Tumor Patients: Cluster Analysis and Application of Risk Scores

Harsha Pattnaik

Poster Presenter: Harsha Pattnaik

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.